期刊
EPIGENOMICS
卷 12, 期 7, 页码 617-646出版社
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2019-0329
关键词
circulating histones; DNA methylation; epigenetic biomarkers; histones PTMs; immunosuppression; miRNAs; PICS; sepsis; septic shock
资金
- VLC-Bioclinics grant 2017
- Generalitat Valenciana [GV/2014/132, GV/2018/127]
- AES2016 (ISCIII) [PI16/01036]
- AES2018 [PI19/0099994]
- Proyectos de Desarrollo Tecnologico en Salud [DTS17/132 AES2017]
- European Regional Development Fund (ERDF)
- Grand Challenges Canada
- Instituto de Salud Carlos III through CIBERer (Biomedical Network Research Center for Rare Diseases)
- Instituto de Salud Carlos III through CIBERer (INGENIO2010)
- la Caixa Foundation through CaixaImpulse 2018 programme [CI18-0009]
Sepsis is a life-threatening condition that occurs when the body responds to an infection damaging its own tissues. Sepsis survivors sometimes suffer from immunosuppression increasing the risk of death. To our best knowledge, there is no 'gold standard' for defining immunosuppression except for a composite clinical end point. As the immune system is exposed to epigenetic changes during and after sepsis, research that focuses on identifying new biomarkers to detect septic patients with immunoparalysis could offer new epigenetic-based strategies to predict short- and long-term pathological events related to this life-threatening state. This review describes the most relevant epigenetic mechanisms underlying alterations in the innate and adaptive immune responses described in sepsis and septic shock, and their consequences for immunosuppression states, providing several candidates to become epigenetic biomarkers that could improve sepsis management and help predict immunosuppression in postseptic patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据